Ideaya Current Deferred Revenue vs Net Working Capital Analysis
IDYA Stock | USD 26.79 0.19 0.71% |
Ideaya Biosciences financial indicator trend analysis is infinitely more than just investigating Ideaya Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ideaya Biosciences is a good investment. Please check the relationship between Ideaya Biosciences Current Deferred Revenue and its Net Working Capital accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.
Current Deferred Revenue vs Net Working Capital
Current Deferred Revenue vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ideaya Biosciences Current Deferred Revenue account and Net Working Capital. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Ideaya Biosciences' Current Deferred Revenue and Net Working Capital is 0.55. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Ideaya Biosciences, assuming nothing else is changed. The correlation between historical values of Ideaya Biosciences' Current Deferred Revenue and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Ideaya Biosciences are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Current Deferred Revenue i.e., Ideaya Biosciences' Current Deferred Revenue and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.55 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Net Working Capital
Most indicators from Ideaya Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ideaya Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.The current year's Enterprise Value is expected to grow to about 2 B, whereas Selling General Administrative is forecasted to decline to about 16.4 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 506K | 3.8M | 21.5M | 22.5M | Net Interest Income | 506K | 3.8M | 21.5M | 22.5M |
Ideaya Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Ideaya Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ideaya Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 113.0M | 298.3M | 381.3M | 388.0M | 649.3M | 681.8M | |
Other Current Liab | 63K | 7.0M | 17.3M | 25.0M | 17.0M | 11.3M | |
Total Current Liabilities | 6.9M | 38.6M | 45.2M | 31.7M | 27.1M | 24.7M | |
Total Stockholder Equity | 100.4M | 198.3M | 301.5M | 349.5M | 621.1M | 652.1M | |
Other Liab | 34K | 56.2M | 31.2M | 5.2M | 6.0M | 5.7M | |
Net Tangible Assets | 100.4M | 198.3M | 301.5M | 349.5M | 401.9M | 422.0M | |
Property Plant And Equipment Net | 9.7M | 9.5M | 8.7M | 9.0M | 8.4M | 8.5M | |
Net Debt | (27.3M) | (65.3M) | (86.9M) | (65.2M) | (154.1M) | (146.4M) | |
Retained Earnings | (92.5M) | (127.0M) | (176.7M) | (235.4M) | (348.4M) | (330.9M) | |
Accounts Payable | 709K | 953K | 2.1M | 4.3M | 6.6M | 6.9M | |
Cash | 34.1M | 72.0M | 92.0M | 68.6M | 157.0M | 164.9M | |
Non Current Assets Total | 12.5M | 9.7M | 130.4M | 17.5M | 116.7M | 122.5M | |
Non Currrent Assets Other | 1.3M | 82K | 397K | 205K | 782K | 416.2K | |
Other Assets | 122K | 188K | 397K | 205K | 184.5K | 239.2K | |
Cash And Short Term Investments | 100.5M | 283.6M | 368.1M | 373.1M | 525.1M | 275.6M | |
Common Stock Total Equity | 2K | 3K | 4K | 5K | 5.8K | 6.0K | |
Common Stock Shares Outstanding | 20.2M | 24.7M | 35.3M | 41.4M | 57.5M | 32.6M | |
Short Term Investments | 64.9M | 211.5M | 154.7M | 296.2M | 368.1M | 184.2M | |
Liabilities And Stockholders Equity | 113.0M | 298.3M | 381.3M | 388.0M | 649.3M | 681.8M | |
Non Current Liabilities Total | 5.7M | 61.4M | 34.7M | 6.8M | 1.1M | 1.1M | |
Capital Surpluse | 192.8M | 325.3M | 479.0M | 587.7M | 675.9M | 709.7M | |
Capital Lease Obligations | 6.8M | 6.7M | 5.2M | 3.5M | 2.9M | 3.9M | |
Other Current Assets | 2.7M | 6.3M | 6.2M | 5.4M | 7.5M | 4.6M | |
Other Stockholder Equity | 79.8M | 325.3M | 479.0M | 587.7M | 968.9M | 1.0B | |
Total Liab | 113.0M | 298.3M | 381.3M | 388.0M | 28.2M | 26.8M | |
Net Invested Capital | 100.4M | 198.3M | 301.5M | 349.5M | 621.1M | 652.1M | |
Property Plant And Equipment Gross | 9.7M | 4.3M | 14.3M | 16.5M | 18.0M | 11.3M | |
Total Current Assets | 100.5M | 288.6M | 251.0M | 370.5M | 532.6M | 559.3M | |
Accumulated Other Comprehensive Income | 65K | 7K | (712K) | (2.9M) | 562K | 590.1K | |
Non Current Liabilities Other | 34K | 12K | 34.7M | 6.8M | 7.8M | 7.7M | |
Net Working Capital | 94.7M | 250.0M | 205.8M | 338.7M | 505.5M | 530.8M | |
Short Term Debt | 1.1M | 3.1M | 3.4M | 3.7M | 3.5M | 2.3M | |
Common Stock | 2K | 3K | 4K | 5K | 7K | 3.6K | |
Property Plant Equipment | 9.7M | 9.5M | 4.8M | 6.5M | 7.5M | 7.2M | |
Capital Stock | 2K | 3K | 4K | 5K | 7K | 3.9K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ideaya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ideaya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ideaya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ideaya Biosciences Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. If investors know Ideaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ideaya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 0.051 | Quarterly Revenue Growth (0.03) | Return On Assets (0.16) | Return On Equity (0.21) |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ideaya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.